• Management of Adverse Effects Associated With Novel Therapies

  • 2022/06/09
  • 再生時間: 13 分
  • ポッドキャスト

Management of Adverse Effects Associated With Novel Therapies

  • サマリー

  • Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.

    続きを読む 一部表示

あらすじ・解説

Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.

Management of Adverse Effects Associated With Novel Therapiesに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。